<DOC>
	<DOCNO>NCT00770965</DOCNO>
	<brief_summary>This exploratory , 4 arm , parallel group , placebo-controlled study compare three dos AIN457 placebo . Subjects diagnosis moderate severe chronic plaque psoriasis randomize receive either AIN457 one three dos study placebo .</brief_summary>
	<brief_title>Phase II Efficacy Study Looking Single-dose One Three Dose Levels AIN457 Patients With Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Diagnosis plaque psoriasis least 6 month prior screen . The patient must meet following criterion : 1 . Coverage body surface area ( BSA ) 10 % plaque 2 . A score 3 IGA ( Investigator Global Assessment ) scale 3 . A PASI score least 12 baseline ; Have form psoriasis require `` plaque psoriasis '' Women childbearing potential Recent use investigational drug treatment biological therapy ( washout period require ) Previous treatment investigational drug Subjects active history clinically significant cardiac , kidney liver abnormalities Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Plaque psoriasis , skin condition , thicken , flake , skin disease , autoimmune disease</keyword>
</DOC>